Ovarian cancer often progresses before symptoms arise, resulting in too many late diagnoses. Given the risk of recurrence, it's important to have an effective second-line therapy for patients who relapse. Immunotherapy is a promising treatment for ovarian cancer is based on several lines of evidence.
In this webinar, John B. Liao, M.D., Ph.D., discusses the immunotherapy landscape for patients with ovarian cancer, and highlight the most effective immunotherapies currently available to patients as well as promising immune-based strategies that have the potential to benefit patients even more.
John B. Liao, M.D., Ph.D., is an assistant professor of obstetrics and gynecology at the University of Washington School of Medicine as well as a practicing gynecologic oncologist affiliated with the Seattle Cancer Care Alliance. Dr. Liao specializes in treating women with gynecologic cancers including cervical, endometrial, and ovarian cancer. His goal is to achieve the best possible care for his patients by tailoring individual treatments and employing a multidisciplinary approach. In pursuit of that goal, he currently serves as the lead investigator of two clinical trials that are combining immunotherapy with chemotherapy to improve patient outcomes.
The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis.
Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.